Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
Circulation · 22.08.2023 · 148 (8) · 651-660
DOI: 10.1161/circulationaha.123.065251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 22.08.2023. Verfasst von James L Januzzi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston (J.L.J., R.M., Y.L.). Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: People with type 2 diabetes and albuminuria are at an elevated risk for cardiac and renal events. The optimal biomarkers to aid disease prediction and to understand the benefits of sodium-glucose cotransporter-2 inhibition remain unclear. METHODS: Among 2627 study participants in the CREDENCE trial (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), concentrations of NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin T, growth differentiation factor-15, and IGFBP7 (insulin-like growth factor binding protein 7) were measured. The effect of canagliflozin on biomarker concentrations was evaluated. The prognostic potential of each biomarker on the primary outcome (a composite of end-stage kidney disease [dialysis, transplantation, or a sustained estimated glomerular filtration rate of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston (J.L.J., R.M., Y.L.).
- Heart Failure and Biomarker Trials, Baim Institute for Clinical Research, Boston, MA (J.L.J.).
- BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK (N.S.).
- Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, the Netherlands (H.J.L.H.).
- Janssen Research & Development, LLC, Spring House, PA (E.T., Y.Y., M.K.H.).
- Cardiology Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.V.).
ORCID-Profile: James L Januzzi, Naveed Sattar, Hiddo J L Heerspink, Muthiah Vaduganathan, Javed Butler, Carol A Pollock, Vlado Perkovic, Bruce Neal, Michael K Hansen
Zitieren
APA
Januzzi, J. L., Mohebi, R., Liu, Y., Sattar, N., Heerspink, H. J. L., Tefera, E., Vaduganathan, M., Butler, J., Yavin, Y., Li, J., Pollock, C. A., Perkovic, V., Neal, B., & Hansen, M. K. (2023). Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial. Circulation, 148(8), 651-660. https://doi.org/10.1161/circulationaha.123.065251
Vancouver
Januzzi JL, Mohebi R, Liu Y, Sattar N, Heerspink HJL, Tefera E, et al. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial. Circulation. 2023;148(8):651-660. doi:10.1161/circulationaha.123.065251
BibTeX
@article{Januzzi2023,
author = {Januzzi, James L and Mohebi, Reza and Liu, Yuxi and Sattar, Naveed and Heerspink, Hiddo J L and Tefera, Eshetu and Vaduganathan, Muthiah and Butler, Javed and Yavin, Yshai and Li, Jingwei and Pollock, Carol A and Perkovic, Vlado and Neal, Bruce and Hansen, Michael K},
title = {Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial},
journal = {Circulation},
year = {2023},
volume = {148},
number = {8},
pages = {651--660},
doi = {10.1161/circulationaha.123.065251}
}
EUVIMED